Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 13Thoracic 1Head & Neck 1Endocrine 1Dermatologic 1

Conditions

Small Cell Lung Carcinoma 1Sarcoma 1Parathyroid Neoplasms 1Neuroendocrine Tumors 1Melanoma 1Carcinoid Tumor 1

Interventions

Fluorodeoxyglucose F18 3Doxorubicin 3Cyclophosphamide 3surufatinib 2fludarabine 2entrectinib 2Radiotherapy 2Nivolumab 2Ifosfamide 2Filgrastim 2Drug Therapy 2Cisplatin 2tivozanib 1tislelizumab 1tipifarnib 1selpercatinib 1romidepsin 1repotrectinib 1regorafenib 1pembrolizumab 1milademetan 1ganitumab 1fludarabine phosphate 1entinostat 1dostarlimab 1conatumumab 1cixutumumab 1cabozantinib 1atezolizumab 1alectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma × Dacarbazine × Endocrine × Clear all
NCT00580320 2016-08-18

Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma

Virginia Commonwealth University

Phase 1 Completed
17 enrolled
DermatologicEndocrineHead & NeckSarcomaThoracic

Carcinoid Tumor, Melanoma, Parathyroid Neoplasms, Sarcoma, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡